Medicine and Dentistry
CYP3A4
100%
Phosphotransferase Inhibitor
100%
Malignant Neoplasm
100%
Single Nucleotide Polymorphism
38%
Drug Dose Reduction
30%
Pharmacokinetics
15%
Personalized Medicine
7%
Clinical Trial
7%
Imatinib
7%
Meta-Analysis
7%
Pazopanib
7%
Genetic Variability
7%
Patient-Data
7%
Steady State
7%
Enzyme Activity
7%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphotransferase Inhibitor
100%
Malignant Neoplasm
100%
CYP3A4
100%
Pharmacokinetics
15%
Imatinib
7%
Clinical Trial
7%
Pazopanib
7%
Immunology and Microbiology
Single Nucleotide Polymorphism
100%
Drug Dose Reduction
80%
Pharmacokinetics
40%
Enzyme Activity
20%
Pazopanib
20%
Patient Coding
20%
Genetic Variability
20%
Steady State
20%